An article in {Cell} reports on an mRNA SARS-CoV-2 vaccine candidate that elicits T cell and antibody responses in animals and has been shown to create immunity in mice. While this is not the first vaccine of its type, its design gives it a one-week shelf life in liquid form at room temperature. This could be a significant advantage in achieving immunization in parts of the world without reliable access to electricity for temperature control — which is itself a situation that must be remedied! https://www.cell.com/cell/
